Local allergic rhinitis: evolution of concepts
AbstractThe discovery of an exclusive local production of IgE antibodies dates back to the 1970s, but only recently the pathophysiology of such phenomenon was deeply investigated, leading to the concept of local allergic rhinitis (LAR). Currently, LAR is defined by the occurrence, in patients with symptoms clearly suggesting allergic rhinitis but with negative results to common allergy testing, of allergen specific IgE in the nasal mucosa. Most studies investigating LAR were based on the development of rhinitis symptoms following nasal provocation test (NPT) with the suspected allergens, but such test may be performed by a...
Source: Clinical and Translational Allergy - November 2, 2017 Category: Allergy & Immunology Source Type: research
CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report
AbstractA Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a c hecklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network f...
Source: Clinical and Translational Allergy - October 23, 2017 Category: Allergy & Immunology Source Type: research
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
DiscussionPrevention of attacks can reduce the burden of illness associated with HAE. Prophylactic therapy requires extended, repeated dosing and the results of this study will provide important data on the long-term safety and efficacy of lanadelumab, a monoclonal antibody inhibitor of plasma kallikrein for subcutaneous administration for the treatment of HAE.Trial registration NCT02741596 (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - October 5, 2017 Category: Allergy & Immunology Source Type: research
The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow ’s milk- and peanut allergy models
ConclusionWe have shown clinical protection against allergic manifestations after OIT and SCIT in a CMA and PNA model. Although similar allergen-specific antibody patterns were observed, differences in T cell and cytokine responses were shown. Whether these findings are related to a different mechanism of AIT in CMA and PNA needs to be elucidated. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - September 29, 2017 Category: Allergy & Immunology Source Type: research
An interpretation of the new international MAP guideline for the management of Milk Allergy in Primary Care
AbstractGeneral Practitioners suffer from guideline fatigue. They come fast and furious in many complicated forms. Cow ’s milk allergy (CMA) is one of the most common presentations of food allergy seen in early childhood presenting to primary and secondary care. The early and accurate diagnosis continues to be highlighted in many countries worldwide. International surveys have found that primary care clinicians wo uld like clearer explanations for the options for the diagnosis of CMA and in so doing a means to increase their understanding of management options for both IgE and Non IgE mediated CMA. In 2013 in response to...
Source: Clinical and Translational Allergy - September 22, 2017 Category: Allergy & Immunology Source Type: research
Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA 2 LEN study
ConclusionPNIF is a helpful and feasible tool for conducting provocation trials with allergens, especially grass pollen and house dust mite, in an AEC. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - September 17, 2017 Category: Allergy & Immunology Source Type: research
Erratum to: Allergen immunotherapy for IgE-mediated food allergy: protocol for a systematic review
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not
acknowledged. This section should be corrected to the below:FundingEAACI and the BM4SIT project (Grant Number 601763) in the European Union ’s Seventh Framework Programme
FP7. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - September 15, 2017 Category: Allergy & Immunology Source Type: research
Erratum to: Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not acknowledged. This section should be corrected to the below:FundingEAACI and the BM4SIT project (Grant Number 601763) in the European Union ’s Seventh Framework Programme FP7. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - September 15, 2017 Category: Allergy & Immunology Source Type: research
Erratum to: Allergen immunotherapy for insect venom allergy: protocol for a systematic review
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not acknowledged. This section should be corrected to the below:FundingEAACI and the BM4SIT project (Grant Number 601763) in the European Union ’s Seventh Framework Programme FP7. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - September 15, 2017 Category: Allergy & Immunology Source Type: research
Erratum to: Allergen immunotherapy for allergic asthma: protocol for a systematic review
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not acknowledged. This section should be corrected to the below:FundingEAACI and the BM4SIT project (Grant Number 601763) in the European Union ’s Seventh Framework Programme FP7. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - September 15, 2017 Category: Allergy & Immunology Source Type: research
Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials
ConclusionsOmalizumab seems to be the most effective therapy in InH-AAE. The continuous decrease of Fc εRI-receptor density on basophils under therapy with omalizumab along with clinical improvement observed in one patient, could serve as a new approach for further studies to evaluate FcεRI-receptor density as a surrogate marker for therapeutic efficacy and for dosing and determining injection inte rvals of omalizumab.Trial registration BASEC-Nr. Req-2016-00692. Retrospectively registered 24.11.2016. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - August 31, 2017 Category: Allergy & Immunology Source Type: research
Abstracts from the 11th Symposium on Experimental Rhinology and Immunology of the Nose (SERIN 2017)
(Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - August 23, 2017 Category: Allergy & Immunology Source Type: research
Better recognition, diagnosis and management of non-IgE-mediated cow ’s milk allergy in infancy: iMAP—an international interpretation of the MAP (Milk Allergy in Primary Care) guideline
Abstract Cow ’s milk allergy (CMA) is one of the most common presentations of food allergy seen in early childhood. It is also one of the most complex food allergies, being implicated in IgE-mediated food allergy as well as diverse manifestations of non-IgE-mediated food allergy. For example, gastrointestinal CMA may present as food protein induced enteropathy, enterocolitis or proctocolitis. Concerns regarding the early and timely diagnosis of CMA have been highlighted over the years. In response to these, guideline papers from the United Kingdom (UK), Australia, Europe, the Americas and the World Aller gy Organisation ...
Source: Clinical and Translational Allergy - August 23, 2017 Category: Allergy & Immunology Source Type: research
Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews
ConclusionsWe found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients, reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and protocols studied. There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT. We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated into the published systematic reviews. (Source: Clini...
Source: Clinical and Translational Allergy - August 8, 2017 Category: Allergy & Immunology Source Type: research
Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews
ConclusionsAIT has the potential to achieve reductions in symptom and medication scores, but there is no clear or consistent evidence that measures of lung function can be improved. Bearing in mind the limitations of synthesizing evidence from systematic reviews and the fact that these reviews include mainly dated studies, a systematic review of current primary studies is now needed to update this evidence base, estimate the effectiveness of AIT on asthma outcomes and to investigate the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - August 1, 2017 Category: Allergy & Immunology Source Type: research
